CrossBridge是一家抗体偶联药物研发商，公司的双有效载荷ADC平台将已建立和新型抗体与各种有效载荷作用机制相结合，开发了一套ADC程序，旨在为一 ...

CrossBridge Bio’s innovative approach to create stable, multi-loaded antibody–drug conjugates is set to generate a suite of first-in-class and best-in-class cancer therapies. Antibody–drug ...

HOUSTON--(BUSINESS WIRE)--CrossBridge Bio, a biotechnology company pioneering dual-payload antibody-drug conjugates (ADCs) as targeted cancer therapies, today announced the closing of a $10 ...

Crossbridge Bio Inc. has closed a $10 million seed financing to support its development of dual-payload antibody-drug conjugates (ADCs) for cancer. The company’s dual-payload ADC platform combines ...

NEW YORK--(BUSINESS WIRE)--Crossbridge Energy A/S (“Crossbridge”) announces that it has reached a final agreement with Everfuel for the offtake of green hydrogen from Everfuel’s anticipated ...